Effects of an Acute 1-month Cannabidiol Treatment on Pain and Inflammation After a Long Bone Fracture: a Triple-blind Randomized, Placebo Controlled Clinical Trial

What this Trial Is About

Researchers are investigating the potential benefits and safety of acute Cannabidiol (CBD) treatment for pain relief following long bone fractures. This trial aims to evaluate how two daily doses of CBD, compared to a placebo, affect pain symptoms, inflammation markers, opioid use, quality of life, sleep quality, mood, cognition, and orthopedic function. The study focuses on adults aged 18 to 70 who have suffered fractures of the upper or lower limbs and explores CBD's potential to reduce chronic pain development and reliance on opioids after trauma. Participants will be randomly assigned to receive either a low dose of 25 mg CBD twice daily, a moderate dose of 50 mg CBD twice daily, or a matching placebo twice daily, all taken orally with meals for one month. The trial is triple-blinded and placebo-controlled to ensure unbiased results. This controlled treatment period is followed by assessments at 4 weeks and 3 months to monitor changes in pain, inflammation, opioid use, and other health-related outcomes. Study participants will undergo multiple evaluations including pain intensity ratings using the Visual Analog Scale (VAS), Brief Pain Inventory, and various cognitive and mood assessments. Researchers will also monitor opioid usage, inflammation blood markers, orthopedic function, sleep quality, depression, anxiety, and cognitive function at baseline, 4 weeks, and 3 months. The total study duration for each participant includes one month of treatment plus follow-up assessments up to 3 months, with safety monitoring throughout the trial.

Cannabidiol After Multi-Trauma for Pain and Opioid Therapy